Management of osteoporosis with calcitriol in elderly Chinese patients: A systematic review

Clinical Interventions in Aging

Volumn 9, Issue , 2014, Pages 515-526

  Liao, Ruo Xi ^a   Yu, Miao ^a   Jiang, Yan ^a   Xia, Weibo ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

Calcitriol; Osteoporosis; Review; Vitamin D; Vitamin D receptor

Indexed keywords

4 CARBOXYGLUTAMIC ACID; ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALENDRONIC ACID; ALKALINE PHOSPHATASE BONE ISOENZYME; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCITRIOL; CALCIUM CARBONATE; CARBOXY TERMINAL TELOPEPTIDE; TIBOLONE; VITAMIN D RECEPTOR; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT; CALCITRIOL RECEPTOR; VDR PROTEIN, HUMAN;

BONE DENSITY; BONE PAIN; BONE TURNOVER; CHINESE; COMBINATION CHEMOTHERAPY; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; ELDERLY CARE; FRACTURE; GENETIC POLYMORPHISM; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; LONG TERM CARE; MONOTHERAPY; MUSCLE FUNCTION; MUSCLE STRENGTH; OSTEOPOROSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TREATMENT RESPONSE; VDR GENE; AGED; CHINA; DRUG EFFECTS; FEMALE; GENETICS; MALE; PHARMACOGENETICS;

AGED; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CALCITRIOL; CHINA; FEMALE; HUMANS; MALE; MUSCLE STRENGTH; OSTEOPOROSIS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; RECEPTORS, CALCITRIOL;

EID: 84897564836     PISSN: 11769092     EISSN: 11781998     Source Type: Journal    
DOI: 10.2147/CIA.S40465     Document Type: Review

References (44)

1. [No authors listed]. [Editorial Board of Osteoporosis Prevention and Treatment (China White Paper)]. Chinese Journal of Health Management. 2009;3(3):148-154. Chinese.
2. Liang Y, Lu Z, Zhang N, Shen L. Evaluation of multi-dimensional outcomes of chronic diseases: a clinical example from China. Arch Gerontol Geriatr. 2011;52(3):106-109.
3. [No authors listed]. [The Chinese guideline for diagnosis and management of osteoporosis]. Chin J Osteoporosis and Bone Miner Res. 2011;4(1):2-17. Chinese.
4. Drissi H, Pouliot A, Koolloos C, etal. 1,25-(OH)2-vitamin D3 suppresses the bone-related Runx2/Cbfa1 gene promoter. Exp Cell Res. 2002;274(2):323-333.
5. Nordin BE. Evolution of the calcium paradigm: the relation between vitamin D, serum calcium and calcium absorption. Nutrients. 2010;2(9): 997-1004.
6. Bikle D, Adams JS, Christakos S. Vitamin D: production, metabolism, mechanism of action and clinical requirements. In: Bikle D, Adams JS, Christakos S, editors. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 8th ed. Ames, IA, USA: Wiley-Blackwell; 2013.
7. Omdahl JL, Bobrovnikova EA, Choe S, Dwivedi PP, May BK. Overview of regulatory cytochrome P450 enzymes of the vitamin D pathway. Steroids. 2001;66(3-5):381-389.
8. Kaneko I, Segawa H, Furutani J, etal. Hypophosphatemia in vitamin D receptor null mice: effect of rescue diet on the developmental changes in renal Na+-dependent phosphate cotransporters. Pflugers Arch. 2011;461(1):77-90.
9. Birge SJ, Haddad JG. 25-hydroxycholecalciferol stimulation of muscle metabolism. J Clin Invest. 1975;56(5):1100-1107.
10. Janssen HC, Samson MM, Verhaar HJ. Vitamin D deficiency, muscle function, and falls in elderly people. Am J Clin Nutr. 2002;75(4): 611-615.
11. Boland R, de Boland AR, Marinissen MJ, Santillan G, Vazquez G, Zanello S. Avian muscle cells as targets for the secosteroid hormone 1,25-dihydroxy-vitamin D3. Mol Cell Endocrinol. 1995;114(1-2):1-8.
12. De Boland AR, Boland RL. Non-genomic signal transduction pathway of vitamin D in muscle. Cell Signal. 1994;6(7):717-724.
13. Vazquez G, de Boland AR, Boland R. Stimulation of Ca2+ release-activated Ca2+ channels as a potential mechanism involved in non-genomic 1,25(OH)2-vitamin D3-induced Ca2+ entry in skeletal muscle cells. Biochem Biophys Res Commun. 1997;239(2):562-565.
14. Geusens P, Vandevyver C, Vanhoof J, Cassiman JJ, Boonen S, Raus J. Quadriceps and grip strength are related to vitamin D receptor genotype in elderly nonobese women. J Bone Miner Res. 1997;12(12): 2082-2088.
15. Silverberg SJ, Shane E, de la Cruz L, Segre GV, Clemens TL, Bilezikian JP. Abnormalities in parathyroid hormone secretion and 1,25-dihydroxyvitamin D3 formation in women with osteoporosis. N Engl J Med. 1989;320(5):277-281.
16. Lidor C, Sagiv P, Amdur B, etal. Decrease in bone levels of 1,25-dihydroxyvitamin D in women with subcapital fracture of the femur. Calcif Tissue Int. 1993;52(2):146-148.
17. Ebeling PR, Sandgren ME, DiMagno EP, Lane AW, DeLuca HF, Riggs BL. Evidence of an age-related decrease in intestinal responsiveness to vitamin D: relationship between serum 1,25-dihydroxyvitamin D3 and intestinal vitamin D receptor concentrations in normal women. J Clin Endocrinol Metab. 1992;75(1):176-182.
18. Prince RL, Dick IM, Lemmon J, Randell D. The pathogenesis of age-related osteoporotic fracture: effects of dietary calcium deprivation. J Clin Endocrinol Metab. 1997;82(1):260-264.
19. Schacht E. Rationale for treatment of involutional osteoporosis in women and for prevention and treatment of corticosteroid-induced osteoporosis with alfacalcidol. Calcif Tissue Int. 1999;65(4):317-327.
20. Haussler MR, Jurutka PW, Mizwicki M, Norman AW. Vitamin D receptor (VDR)-mediated actions of 1alpha,25(OH)(2)vitamin D(3): genomic and non-genomic mechanisms. Best Pract Res Clin Endocrinol Metab. 2011;25(4):543-559.
21. Crofts LA, Hancock MS, Morrison NA, Eisman JA. Multiple promoters direct the tissue-specific expression of novel N-terminal variant human vitamin D receptor gene transcripts. Proc Natl Acad Sci U S A. 1998;95(18):10529-10534.
22. Kurabayashi T, Tomita M, Matsushita H, etal. Association of vitamin D and estrogen receptor gene polymorphism with the effect of hormone replacement therapy on bone mineral density in Japanese women. Am J Obstet Gynecol. 1999;180(5):1115-1120.
23. Zhang HH, Han ZT, Tao GS, etal. [Distribution of vitamin D receptor gene (Bsm I) polymorphisms in healthy postmenopausal women from Han, Uygur, Kazak, Mongoloid population in China]. Chinese Journal of Clinical Rehabilitation. 2006;10(20):160-162. Chinese.
24. 3 in elderly men]. Chinese Journal of Clinical Rehabilitation. 2004;8(33):7469-7471. Chinese.
25. Morrison NA, George PM, Vaughan T, Tilyard MW, Frampton CM, Gilchrist NL. Vitamin D receptor genotypes influence the success of calcitriol therapy for recurrent vertebral fracture in osteoporosis. Pharmacogenet Genomics. 2005;15(2):127-135.
26. Xia WB, Zhang ZL, Wang HF, etal. The efficacy and safety of calcitriol and/or Caltrate D in elderly Chinese women with low bone mass. Acta Pharmacol Sin. 2009;30(3):372-378.
27. Xie AY, Liu TT, Sheng ZF, Liao EY, Zhang H. [The efficacy of combination therapy of calcium carbonate and calcitriol on osteoporosis for postmenopausal women]. China Pharmacist. 2011;(04):546-548. Chinese.
28. He B, He XM, Zhang WJ, Xu L, Wu W. [Research on the preventive effects of calcium and calcitriol on aged patients with osteopenia]. Journal of Sun Yat-Sen University (Medical Sciences). 2009;(S1):193-195. Chinese.
29. Zhu YY, Wang Y, Chu L. [Effect of calcitriol and calcium on prevention and treatment of senile osteoporosis]. China Modern Doctor. 2012;50(7):66-67. Chinese.
30. Yang M, Zhou Y. [The study on the effectiveness of calcitriol in combination with calcium intake for senile osteoporosis]. Modern Journal of Integrated Traditional Chinese and Western Medicine. 2013;22(19):2098-2099. Chinese.
31. Liu L, Zhang DQ, Lin H. [Clinical observation of salmon calcitonin in the treatment of older osteoporotic vertebral compression fracture]. China Modern Doctor. 2013;51(12):71-73. Chinese.
32. Xuan M, Yang J, Li Y, etal. [Effects of zoledronic acid and tibolone on bone mineral density, indexes of bone metabolism, and the risk of fracture in patients with postmenopausal osteoporosis]. Chin J Endocrinol Metab. 2013;29(6):504-508. Chinese.
33. Wang LQ. [Study on the effectiveness of calcitriol in combination with alendronate for osteoporosis]. China Health Care and Nutrition. 2012;9(2):3399-3400. Chinese.
34. Miao DM. [Clinical trial on zolendronic acid therapy on osteoporosis]. China Baojianyingyang. 2012;12(2):599-600. Chinese.
35. Peppone LJ, Hebl S, Purnell JQ, etal. The efficacy of calcitriol therapy in the management of bone loss and fractures: a qualitative review. Osteoporos Int. 2010;21(7):1133-1149.
36. He QH, Zhou XM, Tang C, etal. [Clinical research of calcium and vitamin D3 on treating osteoporosis in middle-aged and old women]. Lab Med Clin. 2011;02:168-169, 171. Chinese.
37. Xu LL, You LM, Yan J. [Quality of life and related factors in patients with osteoporosis]. Journal of Nursing. 2010;17(14):13-18. Chinese.
38. Guo YF, Hu YF, Sun ZQ. [Multiple factor analysis of life quality of postmenopausal osteoporotic women]. Presented at the 2008 China Prevention and Treatment of Common Diseases for The Old Conference, Beijing, People's Republic of China, 2008, June 27-30.
39. Sun ZQ. [Clinical effect evaluation system for age-related diseases]. China Science and Technology Achievements. 2007;(15):58. Chinese.
40. Lian F, Wang Y, Liu YY, etal. [Effects of different therapies on post-menopausal osteoporosis]. Journal of Sun Yat-Sen University (Medical Sciences). 2011;32(3):379-382. Chinese.
41. Cui CY, Wang HG. [Clinical application of calcitriol and adverse reactions]. Chinese Journal of Pharmaceutical Technology Economics and Management. 2008;2(9):69-72. Chinese.
42. Zhu SH, Ying LP. [The efficacy of combination therapy of alendronate and calcitriol on osteoporosis for postmenopausal women]. Modern Practical Medicine. 2011;23(4):441-442. Chinese.
43. Van Etten E, Branisteanu DD, Overbergh L, Bouillon R, Verstuyf A, Mathieu C. Combination of a 1,25-dihydroxyvitamin D3 analog and a bisphosphonate prevents experimental autoimmune encephalomyelitis and preserves bone. Bone. 2003;2(4):397-404.
44. Pei Y, Wang XR, Zhan ZW, etal. [Efficacy analysis of alendronate treatment on postmenopausal osteoporosis]. Chin J Osteoporosis. 2011;17(9):818-820. Chinese.